New insights into renal lipid dysmetabolism in diabetic kidney disease

Lipid dysmetabolism is one of the main features of diabetes mellitus and manifests by dyslipidemia as well as the ectopic accumulation of lipids in various tissues and organs, including the kidney. Research suggests that impaired cholesterol metabolism, increased lipid uptake or synthesis, increased fatty acid oxidation, lipid droplet accumulation and an imbalance in biologically active sphingolipids (such as ceramide, ceramide-1-phosphate and sphingosine-1-phosphate) contribute to the development of diabetic kidney disease (DKD). Currently, the literature suggests that both quality and quantity of lipids are associated with DKD and contribute to increased reactive oxygen species production, oxidative stress, inflammation, or cell death. Therefore, control of renal lipid dysmetabolism is a very important therapeutic goal, which needs to be archived. This article will review some of the recent advances leading to a better understanding of the mechanisms of dyslipidemia and the role of particular lipids and sphingolipids in DKD.

Automated summary

Lipid dysmetabolism is a key feature of diabetes mellitus, including impaired cholesterol metabolism, increased lipid uptake and synthesis, increased fatty acid oxidation, lipid droplet accumulation, and imbalance in biologically active sphingolipids. Controlling renal lipid dysmetabolism is an important therapeutic goal for DKD, as it is associated with increased reactive oxygen species production, oxidative stress, inflammation, and cell death.